UK-based pharmaceutical giant AstraZeneca's COVID-19 vaccine, that was sold in India as Covishield, has been withdrawn worldwide just days after it acknowledged in court documents that its vaccine can cause a rare and dangerous side effect.

AstraZeneca withdraws its Covid vaccine citing commercial reasons

UK scientists have said that the rare blood clot syndrome from AstraZeneca's COVID-19 vaccine has a high mortality rate. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a combination of blot clots and low platelet levels which has been labelled as a rare side effect of the viral vector Covid vaccines made by AstraZeneca and Johnson & Johnson.

Rare blood clot syndrome from AstraZeneca's COVID-19 vaccine has high mortality rate

astrazeneca-vaccine-blood-clot

Astrazeneca Vaccine Blood Clot, News on Astrazeneca Vaccine Blood Clot, stories on Astrazeneca Vaccine Blood Clot, articles on Astrazeneca Vaccine Blood Clot, Astrazeneca Vaccine Blood Clot stories at Wion, Astrazeneca Vaccine Blood Clot news, Astrazeneca Vaccine Blood Clot latest news

astrazeneca vaccine-blood-clot

AstraZeneca withdraws its Covid vaccine citing commercial reasons

Rare blood clot syndrome from AstraZeneca's COVID-19 vaccine has high mortality rate